Stephan Jacob

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats

Erik J. Henriksen, Stephan Jacob, Tyson R. Kinnick et al. · Hypertension · 2001 · 296 citations · Full text

Hypertension, Glucose Tolerance, Insulin Signaling +17

Intramyocellular Lipids: Anthropometric Determinants and Relationships with Maximal Aerobic Capacity and Insulin Sensitivity

Claus Thamer, Jürgen Machann, Oliver Bachmann et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 229 citations · Full text